✦ LIBER ✦

Lenalidomide active in myelodysplastic syndrome without 5q deletion

Book ID: 120845495
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816230-00040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide in the Myelodysplastic Synd

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

✍ List, Alan; Dewald, Gordon; Bennett, John; Giagounidis, Aristotle; Raza, Azra; F 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 203 KB

Myelodysplastic syndromes with 5q deleti

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

✍ Gaballa, Mahmoud R.; Besa, Emmanuel C. 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 631 KB

Lenalidomide on alternative days is effe

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion

✍ Marzia Defina; Michela Rondoni; Alessandro Gozzetti; Lara Aprile; Ida Chitarrell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Treatment by Lenalidomide in lower risk

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

✍ Fabien Le Bras; Marie Sebert; Charikleia Kelaidi; Thierry Lamy; François Dreyfus 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 197 KB

Lenalidomide for del(5q) and Non-del(5q)

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

✍ Aristoteles A.N. Giagounidis 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Lenalidomide in 5q minus myelodysplastic

Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

✍ Donat Dürr; Raffaele Daniele Siciliano; Yvonne Hummel; Alix O’Meara; Anita Hirsc 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 65 KB